TITLE:
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

CONDITION:
Lymphoma, B-Cell

INTERVENTION:
Inotuzumab ozogamicin [CMC-544]

SUMMARY:

      To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety
      profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according
             to WHO classification, which has progressed after at least 2 prior therapies of
             probable clinical benefit

          -  At the expanded cohort, part 2 of the study, subjects must have one of the following:

          -  Follicular lymphoma previously treated with at least one dose of rituximab, but have
             not received radioimmunotherapy

          -  Diffuse large B-cell lymphoma

          -  Age 18 years or older

        Exclusion Criteria:

          -  Candidate for potentially curative therapies in the opinion of the investigator

          -  Chronic lymphocytic leukemia

          -  Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic
             lymphoma
      
